Back to search

Peptide record

TPDB09023

Antibacterial Antifungal Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09023
Antibacterial Antifungal Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AFP-GFuse Antifungipept CAFPdb
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Antifungal, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
VNFKLLSHSLLVTLASHL
Physicochemical Analysis
C93H154N24O24
RDCEQGIMPWY
L
1992.39
10.10
3
0
10
+1
-0.66
1.050
167.78
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
5
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
0
E
0
Q
0
G
2
H
0
I
6
L
1
K
0
M
1
F
0
P
3
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 2 I: 0 L: 6 K: 1 M: 0 F: 1 P: 0 S: 3 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
18
C93H154N24O24
1992.39
10.10
+1
-0.66
1.050
Evidence Records 13 records
Evidence 1 Activity

Activity

MIC
Antibacterial
12.5 µg/mL

Target

Escherichia coli ATCC 25922 or clinical strain

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli ATCC 25922 or clinical strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical stra
Evidence 2 Activity

Activity

MIC
Antibacterial
12.5-25 µg/mL

Target

Staphylococcus aureus ATCC 29213 or clinical strain

Source & Reference

dbAMP DRAMP

Other

Active against E. coli ATCC 25922 or clinical strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical stra
Evidence 3 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

Pseudomonas aeruginosa clinical strain

Source & Reference

dbAMP DRAMP

Other

cal strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical strain (MIC 50 ug/ml). Updated 7/2021 merged 5/20
Evidence 4 Activity

Activity

MIC
Antibacterial
50 µg/mL

Target

Candida albicans ATCC 90029 or cinical strain

Source & Reference

dbAMP DRAMP

Other

or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical strain (MIC 50 ug/ml). Updated 7/2021 merged 5/2023
Evidence 5 Activity

Activity

MIC
Antifungal
12.5 µg/mL

Target

Escherichia coli ATCC 25922 or clinical strain

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli ATCC 25922 or clinical strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical stra
Evidence 6 Activity

Activity

MIC
Antifungal
12.5-25 µg/mL

Target

Staphylococcus aureus ATCC 29213 or clinical strain

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli ATCC 25922 or clinical strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical stra
Evidence 7 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

Pseudomonas aeruginosa clinical strain

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

cal strain (MIC 12.5 ug/ml), S. aureus ATCC 29213 or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical strain (MIC 50 ug/ml). Updated 7/2021 merged 5/20
Evidence 8 Activity

Activity

MIC
Antifungal
50 µg/mL

Target

Candida albicans ATCC 90029 or cinical strain

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

or clinical strain (MIC 12.5-25 ug/ml), P. aeruginosa clinical strain (MIC 25 ug/ml), and C. albicans ATCC 90029 or cinical strain (MIC 50 ug/ml). Updated 7/2021 merged 5/2023
Evidence 9 Activity

Activity

5% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 100 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Potential of novel antimicrobial peptide P3 from bovine erythrocytes and its analogs to disrupt bacterial membranes in vitro and display activity against drug-resistant bacteria in a mouse model. | Antimicrob Agents Chemother | 2015
Evidence 10 Activity

Activity

7% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
7% Hemolysis | 200 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Evidence 11 Activity

Activity

8% Killing
Toxicity
100 µg/mL
Cytotoxic
8% Killing | 100 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Potential of novel antimicrobial peptide P3 from bovine erythrocytes and its analogs to disrupt bacterial membranes in vitro and display activity against drug-resistant bacteria in a mouse model. | Antimicrob Agents Chemother | 2015
Evidence 12 Activity

Activity

12% Killing
Toxicity
200 µg/mL
Cytotoxic
12% Killing | 200 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Potential of novel antimicrobial peptide P3 from bovine erythrocytes and its analogs to disrupt bacterial membranes in vitro and display activity against drug-resistant bacteria in a mouse model. | Antimicrob Agents Chemother | 2015
Evidence 13 Activity

Activity

% Hemolysis
Toxicity
3 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.25753638] 3% hemolysis at 50 µg/ml , 5% hemolysis at 100 µg/ml , 7% hemolysis at 200 µg/ml , 7.5% hemolysis at 300 µg/ml , 8% hemolysis at 400 µg/ml against human red blood cells | Cytotoxicity: [Ref.25753638] The cell viability of HaCaT cell lines is 93% and 94% at peptide concentrations of 200 and 400 µg/ml. In kumning mice, the LD50 of P3 is 160 mg/kg for i.p. injection, while the LD50 of PMB(served as a control) is 50 mg/kg. No mortality w

Target

erythrocytes

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2015 May 59(5):2835-41. doi: 10.1128/AAC.04932-14.